Faruqi & Faruqi, LLP’s national practice focuses on complex civil litigation. The firm practices in the areas of Securities, Merger & Transactional, Shareholder Derivative, Antitrust, Consumer Class Action, and Wage & Hour litigation.
Monday, May 11, 2015
Faruqi & Faruqi Investigation: Aerie Pharmaceuticals, Inc.
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aerie Pharmaceuticals, Inc. (AERI) To Contact The Firm
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose material adverse information about the future prospects for its once-daily eye drop medication Rhopressa, designed to lower intraocular pressure (“IOP”) in patients with glaucoma or ocular hypertension.
On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the press release, “
[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”
Following this unexpected news, shares of Aerie’s stock fell $22.52 per share, or over 63%, to close on April 24, 2015 at $12.87 per share.
If you invested in Aerie stock or options between August 6, 2014 and April 23, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Aerie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.